PBS Frontline, and more on "Medicare for All"

PBS aired a provocative Frontline program  last week detailing many of the woes of patients with serious illnesses under the current employer-based health insurance system.   A talented college senior gives up on engineering and settles for a job selling lamps because it offers good coverage.  A middle age man loses his house, declares bankruptcy and has to move in with his mother after he lost his job and required bypass surgery. A self-employed woman finds her high-deductible high-premium insurance plan revoked retroactively based on a technicality, after she has a severely premature baby with very expensive medical needs.  The CEO of a health plan which insures millions reveals that because of his history of heart disease, he himself could not qualify to purchase health insurance as an individual.  The Kaiser Family Foundation,  one of the most savvy health care policy groups, had to shop its insurance to another health plan when one of its employees had a sick baby and premiums skyrocketed!

 

The program does a good job of focusing attention on the equity issues of underwriting in our current health care finance system.  On one hand, it’s not fair for a health plan (or the other subscribers to a health plan) to have to provide full coverage for a patient who signed up after they already knew about their illness.  On the other hand – illness is already a substantial punishment, and it doesn’t seem right to also saddle the sick with enormous bills. It’s also not practical, because those with substantial illness are least able to pay such bills.   Clearly, coupling a mandate to have health insurance with the elimination of medical underwriting is an attractive solution.  It spreads the risk among many healthy people (critical to the “insurance” nature of health insurance), while dramatically decreasing the rate of uninsured patients.  This is what the health insurance industry is currently advocating, and is incorporated into health care reform in Massachusetts.


The PBS show also quotes Uwe Reinhart, an economist at Princeton, who states that total administrative costs in the American system is 24% - substantially higher than other countries.  Most observers think that the cost of administration of health care is the cost of administering health plans (administrative services plus profit).  In fact, the administrative cost is a combination of the health plan administrative costs AND administrative costs on the provider side – and it seems perfectly possible that providers spend as much on billing as health plans spend on paying those bills.   Since little of this administration adds value for patients, administrative simplification will be critical.  I’m hopeful that bundling payments will allow for some degree of administrative simplification, although even in capitation it’s important to have a “claims-like” process to facilitate for quality control and health services research.

 

There continues to be a call for a public insurance plan (see today’s NYTimes editorial)  I continue to worry that the main reason a government-sponsored plan is less expensive is cost-shifting to other plans – which would become impossible if we had “Medicare for all.”   See previous post on how health plans can add value, and a podcast on this subject. 


 

 

 

 

 

Transparency in Massachusetts: A Success and a Challenge

Today, Massachusetts Health Quality Partners releases its fifth annual report on quality of medical groups across the state.   The quality data is derived from claims data from most of the health insurers in the state (not including Medicare or Medicaid).  MHQP also reports on patient experience data based on an annual survey.  MHQP’s database is searchable by name and zip code. 

 

Patients in Massachusetts can see quality and patient experience metrics for medical groups. This makes the data more likely to be statistically significant, although some critics would rather see this data at the individual physician level.  The value of a report at the group level is especially high for practices with high levels of integration and cross-coverage.  MHQP has established dialog with physicians, health plans, and other stakeholders, and gives providers a cycle to review and comment on data before it is publicly released. This takes time and energy – but increased “buy-in” from the provider community makes it more likely that the public disclosure will actually change practice. 

 

MHQP will be developing and implementing the state’s quality and cost website over the coming months.  Data on cost of care will be an important complement to the current public disclosure.

 

The Boston Globe had a front page article yesterday suggesting that cardiologists in Massachusetts avoid the “tough” cases of heart vessel blockage for fear that these cases would adversely impact their reported mortality rates.   (In an ideal world risk adjustment would fully address this concern – but we don’t live in an ideal world!)   The article was illustrated with a photograph of a man who had an angioplasty despite the fact that he was in a coma – he recovered and is shown with his wife walking the family’s three dogs.

 

This is a tough public policy issue.  There is very ample evidence that public reporting helps ease “bad quality” providers out of the system, and lowers the risk of death or morbidity for the “average” patient.  However, there is also evidence that public reporting makes physicians at tertiary centers ambivalent about performing at the “cutting edge.”  Many feel that some heroic care offered at academic medical centers is wasteful and seems cruel to dying patients and their families.  However, the “frontier” of medical treatment really does move based on this “cowboy” medicine.  When I was in medical school, treatment of premature newborns under 2 pounds seemed futile; now, such babies are routinely saved, and many go on to lives that are not even marred by severe disability.  Great essay on this by Tom Lee and others "Is Zero The Ideal Death Rate?"

 

Since public reporting of cardiac surgery, the mortality and morbidity of that surgery has plummeted.  I’m hopeful that the cardiologists will get behind improved risk adjustment and support public reporting of outcomes from angioplasties.   Perhaps in the end we'll have to just remove the highest risk cases from reporting - rather than pinning our hopes on risk adjustment. 

 

Prostate Cancer Screening: Rough Estimate of the Cost

Two studies in last week’s  New England Journal Of Medicine showed disappointing results from prostate cancer screening. This is a reminder that investments in preventive care are not always a good idea.  The United States study, completed in 10 centers, included 77,000 patients and showed a nonsignificant increase in death rates among those patients who were randomly assigned to screening.  The European study, an amalgam of seven different studies which had different designs, included 182,000 patients, and did show a decrease in death from prostate cancer of 7 per 10,000. However, 49 men were treated for prostate cancer for each life saved – leading to an enormous amount of incontinence and impotence. 

 

I’ll turn 50 next year – and it’s not looking like I’ll be getting my first PSA test!

 

The morbidity from all prostate cancer treatment is considerable – whether prostate removal (radical prostatectomy) or radiation (either external beam or implantation of radiation ‘seeds’).  There is has been little written about the cost of the increased cancer diagnosis from  prostate cancer screening – so I figured I would provide some “back of the envelope” guesstimates of the cost of our prostate cancer screening.

 

Population:  18.7 million  ages 50-59 (United States)


Increased Cancer Diagnoses: 3.4% (8.2% in the screening group and 4.8% in the control group)


è Increased Cancer diagnoses: 638,542 for this population over about a decade

 

Distribution of Treatment (and associated cost)

Wilson, et al Cumulative cost pattern comparison of prostate cancer treatments, Cancer 109: 18-527


Note that this is Medicare data, so this understates the cost compared to a population under 65.

 

è Total excess cost over 10 years for this population: $27 billion

 

That’s not a trivial figure even in these days of massive corporate bailouts.


 

 

%age

Cost

#

Spend

Radical Prostatectomy

55%

 $        36,888

         350,055

 $  12,912,828,840

Cryotherapy

3%

 $        43,108

           18,933

 $        816,163,764

Brachytherapy

15%

 $        35,143

           93,684

 $    3,292,336,812

External Beam

9%

 $        59,455

           57,360

 $    3,410,338,800

Androgen

13%

 $        69,244

           85,129

 $    5,894,672,476

Watchful Wait

5%

 $        32,135

           33,378

 $    1,072,602,030

TOTAL INCREASED SPENDING

 

 

 

 $  27,398,942,722